References
- MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr. 1995;5:127-56 https://doi.org/10.1615/CritRevEukarGeneExpr.v5.i2.20
- Ahn JG, Lee TS, Cho JW, Baek WK, Suh SI, Suh MH, et al. Expression of cell cycle control genes in human uterine cervical cancer cells. J Korean Cancer Assoc. 2000;32:110-9
- Kelland LR. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Expert Opin Investig Drugs. 2000;9:2903-11 https://doi.org/10.1517/13543784.9.12.2903
- Worland PJ, Kaur G, Stetler-Stevenson M, Sebers S, Sartor O, Sausville EA. Alteration of the phosphorylation stte of p34cdc2 kinase by flavone L86-8275 in breast carcinoma cell. Correlation with decreased H1 kinase activity. Biochem Pharmacol. 1993;46:1831-40 https://doi.org/10.1016/0006-2952(93)90590-S
- Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun. 1994;201:589-95 https://doi.org/10.1006/bbrc.1994.1742
- Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Flavopiridol induces G1 arrest with inhibition of cyclindependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996;56:2973-8
- Meijer L, Kim SH. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol. 1997;283:113-128 https://doi.org/10.1016/S0076-6879(97)83011-X
- Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, et al. Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst. 1992;84:1736-1340
- Blagosklonny MV, Darzynkeiwicz Z, Figg WD. Flavopiridol inversely affects p21(WAF1/CIP1) and p53 protects p21-sensitive cells from paclitaxel. Cancer Biol Ther. 2002;1:420-5 https://doi.org/10.4161/cbt.1.4.21
- Shapiro GI, Koestner DA, Matranga CB, Rollins BJ. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res. 1999;5:2925-38
- Alonso M, Tamasdan C, Miller DC, Newcomb EW. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther. 2003;2:139-50
- Newcomb EW, Tamasdan C, Entzminger Y, Alonso J, Friedlander D, Crisan D, et al. Flavopiridol induces mitochondrial-mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell Cycle. 2003;2:243-50
-
Takaya Y, Aggrawal BB. Flavopiridol inhibits NF-
${\kappa}B$ activation induced by various carcinogens and inflammatory agents through inhibition of$I{\kappa}B{\alpha}$ and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2 and matrix metalloprotease-9. J Biol Chem. 2004;279:4750-9 https://doi.org/10.1074/jbc.M304546200 - Patel V, Senderowicz AM, Pinto D Jr, Igishi T, Raffeld M, Quintanilla-Martinez L. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J Clin Invest. 1998;102:1674-81 https://doi.org/10.1172/JCI3661
- Melillo G, Sausville EA, Cloud K, Lahusen T, Varsio L, Senderowicz AM. Flavopiridol, a protein kinase inhibitor, downregulates hypoxic induction of vascular endothelial growth factor expression in human monocytes. Cancer Res. 1999;59:5433-7
- Bible KC, Kaufmann SH. Cytotoxic synergy between Flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 1997;57:3375-80
- Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res. 1999;5:1876-83
-
Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in
$Apc^{\delta}716$ knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996;87:803-9 https://doi.org/10.1016/S0092-8674(00)81988-1 -
Jung C, Motwani M, Kortmansky J, Sirotnak FM, She Y, Gonen M, et al. The cyclin-dependent kinase inhibitor flavopiridol potentiates
${\gamma}$ -irradiation-induced apoptosis in colon and gastric cancer cells. Clin Cancer Res. 2003;9:6052-61 - Newcomb EW. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anti-cancer Drugs. 2004:15;411-9 https://doi.org/10.1097/01.cad.0000127332.06439.47
- Sedlacek HH, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, et al. Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol. 1996;9:1143-68
- Czech J, Hoffmann D, Naik R, Sedlacek HH. Antitumoral activity of flavone L86 8275. Int J Oncol. 1995;274:1664-72
- Motwani M, Jung C, Sirotnak FM, She Y, Shah MA, Gonen M, et al. Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in HCT-116 colon cancer monolayers and xenografts. Clin Cancer Res. 2001;7:4209-19
- Mason KA, Hunter NR, Raju U, Ariga H, Husain A, Valdecanas D, et al. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse. Int J Radiat Oncol Biol Phys. 2004;59:1181-9 https://doi.org/10.1016/j.ijrobp.2004.03.003
- Kim JC, Saha D, Cao Q, Choy H. Enhancement of radiation effects by combined docetaxel and flavopiridol treatment in lung cancer cells. Radiother Oncol. 2004;71:213-21 https://doi.org/10.1016/j.radonc.2004.03.006